Summit Therapeutics (SMMT) Tops Q3 EPS by 4c
Tweet
Share
E-mail
Get Alerts SMMT Hot Sheet
Join SI Premium – FREE
Summit Therapeutics (NASDAQ: SMMT) reported Q3 EPS of (GBP0.13), GBP0.04 better than the analyst estimate of (GBP0.17).
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regency Centers (REG) Tops Q2 EPS by 2c
- Contineum Therapeutics, Inc. (CTNM) Tops Q2 EPS by 4c
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
